×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
TSE:MDNA

Medicenna Therapeutics Stock Forecast, Price & News

C$1.48
-0.08 (-5.13%)
(As of 06/30/2022 12:00 AM ET)
Add
Compare
Today's Range
C$1.48
C$1.56
50-Day Range
C$0.99
C$1.67
52-Week Range
C$0.98
C$3.82
Volume
17,500 shs
Average Volume
29,977 shs
Market Capitalization
C$83.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$8.50

Medicenna Therapeutics Stock Forecast (MarketRank)

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
474.3% Upside
C$8.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.55 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Medicenna Therapeutics logo

About Medicenna Therapeutics (TSE:MDNA)

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

MDNA Stock News Headlines

CIG, GRTX and MDNA among pre market gainers
Medicenna Therapeutics Corp. (MDNA)
Medicenna to Commence Trading on Nasdaq
Medicenna Therapeutics Corp. (MDNAF)
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Company Calendar

Today
7/02/2022
Next Earnings (Estimated)
8/11/2022

Price Target and Rating

Average Stock Price Forecast
C$8.50
High Stock Price Forecast
C$14.00
Low Stock Price Forecast
C$4.00
Forecasted Upside/Downside
+474.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.42 per share
Book Value
C$0.43 per share

Miscellaneous

Free Float
N/A
Market Cap
C$83.33 million
Optionable
Not Optionable
Beta
N/A














Medicenna Therapeutics Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medicenna Therapeutics stock.
View analyst ratings for Medicenna Therapeutics
or view top-rated stocks.

What is Medicenna Therapeutics' stock price forecast for 2022?

4 analysts have issued twelve-month target prices for Medicenna Therapeutics' shares. Their MDNA stock forecasts range from C$4.00 to C$14.00. On average, they anticipate Medicenna Therapeutics' share price to reach C$8.50 in the next year. This suggests a possible upside of 474.3% from the stock's current price.
View analysts' price targets for Medicenna Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Medicenna Therapeutics' stock price performed in 2022?

Medicenna Therapeutics' stock was trading at C$2.10 on January 1st, 2022. Since then, MDNA stock has decreased by 29.5% and is now trading at C$1.48.
View the best growth stocks for 2022 here
.

When is Medicenna Therapeutics' next earnings date?

Medicenna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Medicenna Therapeutics
.

Who are Medicenna Therapeutics' key executives?

Medicenna Therapeutics' management team includes the following people:
  • Dr. Fahar Merchant Ph.D., Founder, Chairman, CEO & Pres (Age 65, Pay $569.38k)
  • Ms. Rosemina Merchant B.Sc., M.E.Sc, Founder, Chief Devel. Officer & Director (Age 65, Pay $465.77k)
  • Ms. Elizabeth Williams C.A., CPA, CA, CPA, CFO & Corp. Sec. (Age 44, Pay $360.88k)
  • Dr. Martin Bexon M.D., MBBS, Acting Chief Medical Officer & Head of Clinical Devel.
  • Dr. Samuel R. Denmeade M.D., Scientific Advisor

What other stocks do shareholders of Medicenna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), (ATE), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO).

What is Medicenna Therapeutics' stock symbol?

Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA."

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Medicenna Therapeutics' stock price today?

One share of MDNA stock can currently be purchased for approximately C$1.48.

How much money does Medicenna Therapeutics make?

Medicenna Therapeutics (TSE:MDNA) has a market capitalization of C$83.33 million.

How many employees does Medicenna Therapeutics have?

Medicenna Therapeutics employs 13 workers across the globe.

How can I contact Medicenna Therapeutics?

Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The official website for Medicenna Therapeutics is www.medicenna.com. The company can be reached via phone at +1-403-6807898.

This page (TSE:MDNA) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.